Lurbinectedin Phase 3 LAGOON Trial for Relapsed SCLC Completes Primary Study

The Phase 3 LAGOON trial (NCT05153239) investigating lurbinectedin as a treatment for relapsed small-cell lung cancer completed its primary study on April 30, 2026. This multicenter, open-label, randomized, controlled trial enrolled 705 participants to compare lurbinectedin regimens against investigator's choice of standard therapies.

Background

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options, especially after initial therapy failure. The LAGOON trial specifically focuses on patients with relapsed SCLC who have failed one prior platinum-containing line of therapy, addressing a critical need for further treatment options in this challenging patient population.

Trial design

The LAGOON study (NCT05153239) is a Phase 3, multicenter, open-label, randomized, controlled clinical trial that enrolled 705 participants. The study investigates lurbinectedin as a single agent or in combination with irinotecan for patients with relapsed small-cell lung cancer who have failed one prior platinum-containing line of therapy. Comparator arms include investigator's choice of either topotecan or irinotecan.

What this means

The primary completion of the LAGOON trial marks a significant milestone in the evaluation of lurbinectedin for relapsed small-cell lung cancer. While specific results are not yet available, the completion of this Phase 3 study indicates that data collection for the primary endpoints is concluded. The findings from this trial will be crucial in understanding the potential role of lurbinectedin, both as a monotherapy and in combination, for patients with this challenging cancer, potentially offering new therapeutic strategies.

Source

The information regarding the primary completion of the LAGOON trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05153239, titled "Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)," was posted on April 30, 2026 on clinicaltrials.gov.